ProQR Therapeutics (PRQR) Operating Leases (2021 - 2025)

ProQR Therapeutics (PRQR) has disclosed Operating Leases for 5 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 6.03% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Dec 2025, down 6.03% year-over-year, with the annual reading at $11.1 million for FY2025, 6.03% down from the prior year.
  • Operating Leases hit $11.1 million in Q4 2025 for ProQR Therapeutics, down from $11.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $16.9 million in Q4 2021 to a low of $11.1 million in Q4 2025.
  • Historically, Operating Leases has averaged $13.8 million across 5 years, with a median of $14.1 million in 2022.
  • Biggest five-year swings in Operating Leases: grew 5.57% in 2023 and later dropped 20.51% in 2024.
  • Year by year, Operating Leases stood at $16.9 million in 2021, then decreased by 16.47% to $14.1 million in 2022, then rose by 5.57% to $14.9 million in 2023, then fell by 20.51% to $11.8 million in 2024, then dropped by 6.03% to $11.1 million in 2025.
  • Business Quant data shows Operating Leases for PRQR at $11.1 million in Q4 2025, $11.8 million in Q4 2024, and $14.9 million in Q4 2023.